Literature DB >> 14764739

TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens.

Valérie S Zimmermann1, Attilio Bondanza, Antonella Monno, Patrizia Rovere-Querini, Angelo Corti, Angelo A Manfredi.   

Abstract

The cross-presentation of Ags derived from apoptotic cell processing contributes to peripheral tolerance. Environmental signals possibly modify this default outcome, favoring cross-priming. In this study, we anchored via a biotin-avidin-biotin bridge soluble TNF-alpha to the membrane of apoptotic melanoma cells and studied in vivo and in vitro the interaction with Ag-presenting phagocytes. TNF-alpha-coated apoptotic melanoma cells injected s.c. had a faster and more efficient access to draining lymph nodes, with cross-priming of melanoma-specific CTLs and delayed outgrowth of melanomas in all treated animals. Twenty percent of the animals, in the absence of further adjuvant, did not develop the tumor. Immature dendritic cells challenged with TNF-alpha-coated apoptotic melanoma cells secreted proinflammatory cytokines in an autocrine/paracrine fashion, efficiently matured, as assessed functionally and by flow cytometry and cross-presented with enhanced efficiency melanoma Ags to MHC class I- and II-restricted T cells. The results indicate that TNF-alpha targeted to apoptotic membranes, at concentrations that can be safely reached in growing tumors without undue systemic toxicity, influences the outcome of the disposal of dying cells and enhances tumor immunogenicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764739     DOI: 10.4049/jimmunol.172.4.2643

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Regulation of the lifespan in dendritic cell subsets.

Authors:  Min Chen; Li Huang; Zainuer Shabier; Jin Wang
Journal:  Mol Immunol       Date:  2007-01-30       Impact factor: 4.407

Review 2.  Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Authors:  Joseph M Cicchese; Stephanie Evans; Caitlin Hult; Louis R Joslyn; Timothy Wessler; Jess A Millar; Simeone Marino; Nicholas A Cilfone; Joshua T Mattila; Jennifer J Linderman; Denise E Kirschner
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

Review 3.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

4.  Chimeric form of tumor necrosis factor-alpha has enhanced surface expression and antitumor activity.

Authors:  R Rieger; D Whitacre; M J Cantwell; C Prussak; T J Kipps
Journal:  Cancer Gene Ther       Date:  2008-07-25       Impact factor: 5.987

5.  Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.

Authors:  Lili Chen; Zhengxiang He; Li Qin; Qinyan Li; Xibao Shi; Siting Zhao; Ling Chen; Nanshan Zhong; Xiaoping Chen
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

6.  Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray.

Authors:  Daniel S Chen; Yoav Soen; Tor B Stuge; Peter P Lee; Jeffrey S Weber; Patrick O Brown; Mark M Davis
Journal:  PLoS Med       Date:  2005-09-20       Impact factor: 11.069

7.  Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo.

Authors:  Attilio Bondanza; Valérie S Zimmermann; Patrizia Rovere-Querini; Javier Turnay; Ingrid E Dumitriu; Christian M Stach; Reinhard E Voll; Udo S Gaipl; Wolf Bertling; Ernst Pöschl; Joachim R Kalden; Angelo A Manfredi; Martin Herrmann
Journal:  J Exp Med       Date:  2004-10-25       Impact factor: 14.307

8.  Sustained cross-presentation capacity of murine splenic dendritic cell subsets in vivo.

Authors:  Nataschja I Ho; Marcel G M Camps; Edwin F E de Haas; Ferry Ossendorp
Journal:  Eur J Immunol       Date:  2018-05-17       Impact factor: 5.532

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.